Abstract
The intent of this article is to summarize current body of knowledge on the potential implication of the xanthine oxidase pathway (XO) on skeletal muscle damage. The possible involvement of the XO pathway in muscle damage is exemplified by the role of XO inhibitors (e.g., allopurinol) in attenuating muscle damage. Reliance on this pathway (as well as on the purine nucleotide cycle) could be exacerbated in conditions of low muscle glycogen availability. Thus, we also summarize current hypotheses on the etiology of both baseline and exertional muscle damage in McArdle disease, a condition caused by inherited deficiency of myophosphorylase. Because myophosphorylase catalyzes the first step of muscle glycogen breakdown, patients are unable to obtain energy from their muscle glycogen stores. Finally, we provide preliminary data from our laboratory on the potential implication of the XO pathway in the muscle damage that is commonly experienced by these patients.
Keywords: McArdle disease, xanthine oxidase, muscle damage, rhabdomyolysis, oxidative stress.
Current Pharmaceutical Design
Title:Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease
Volume: 22 Issue: 18
Author(s): Helios Pareja-Galeano, Alejandro Santos-Lozano, María Morán, Fabian Sanchis-Gomar, Rafael Alis, Alfredo Santalla, Alejandro F. San Juan, Jorge Díez-Bermejo, Miguel A. Martín, Joaquín Arenas and Alejandro Lucia
Affiliation:
Keywords: McArdle disease, xanthine oxidase, muscle damage, rhabdomyolysis, oxidative stress.
Abstract: The intent of this article is to summarize current body of knowledge on the potential implication of the xanthine oxidase pathway (XO) on skeletal muscle damage. The possible involvement of the XO pathway in muscle damage is exemplified by the role of XO inhibitors (e.g., allopurinol) in attenuating muscle damage. Reliance on this pathway (as well as on the purine nucleotide cycle) could be exacerbated in conditions of low muscle glycogen availability. Thus, we also summarize current hypotheses on the etiology of both baseline and exertional muscle damage in McArdle disease, a condition caused by inherited deficiency of myophosphorylase. Because myophosphorylase catalyzes the first step of muscle glycogen breakdown, patients are unable to obtain energy from their muscle glycogen stores. Finally, we provide preliminary data from our laboratory on the potential implication of the XO pathway in the muscle damage that is commonly experienced by these patients.
Export Options
About this article
Cite this article as:
Pareja-Galeano Helios, Santos-Lozano Alejandro, Morán María, Sanchis-Gomar Fabian, Alis Rafael, Santalla Alfredo, F. San Juan Alejandro, Díez-Bermejo Jorge, A. Martín Miguel, Arenas Joaquín and Lucia Alejandro, Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease, Current Pharmaceutical Design 2016; 22 (18) . https://dx.doi.org/10.2174/1381612822666160210144419
DOI https://dx.doi.org/10.2174/1381612822666160210144419 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Treatment and Outcome of Pulmonary Arterial Hypertension in HIVInfected Patients: A Review of the Literature
Current HIV Research The Role of Oxidative Stress Modulators in Breast Cancer
Current Medicinal Chemistry Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Modulation of Cellular Response to Anticancer Treatment by Caffeine: Inhibition of Cell Cycle Checkpoints, DNA Repair and More
Current Pharmaceutical Biotechnology Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Mechanisms of Endothelial Dysfunction: Clinical Significance and Preventive Non-Pharmacological Therapeutic Strategies
Current Pharmaceutical Design Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design Pharmacological Potential of Tetrahydrofurano/Pyrano Quinoline and Benzo[b]furoindolyl Derivatives in Acute Inflammation, Pain and Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Application of Nanomedicine in Cardiovascular Diseases and Stroke
Current Pharmaceutical Design The Chemical Biology of Immunophilin Ligands
Current Medicinal Chemistry Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets